TYK2 and COVID-19: In contrast, the anti-inflammatory therapy baricitinib, which has activity against JAK1/2 and moderate activity against TYK2, reduced mortality amongst hospitalized patients with COVID-19 by about 20%, and it has received U.S. Food and Drug Administration (FDA) approval for this indication (151).